BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32641749)

  • 21. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
    Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
    Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HAX-1 promotes the migration and invasion of hepatocellular carcinoma cells through the induction of epithelial-mesenchymal transition via the NF-κB pathway.
    Hu YL; Feng Y; Ma P; Wang F; Huang H; Guo YB; Li P; Mao QS; Xue WJ
    Exp Cell Res; 2019 Aug; 381(1):66-76. PubMed ID: 31047882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
    Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
    BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.
    Xu L; Wang P; Feng X; Tang J; Li L; Zheng X; Zhang J; Hu Y; Lan T; Yuan K; Zhang Y; Ren S; Hao X; Zhang M; Xu M
    Clin Sci (Lond); 2019 Oct; 133(20):2085-2105. PubMed ID: 31654063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
    Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
    Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.
    Zhong FJ; Li YM; Xu C; Sun B; Wang JL; Yang LY
    Clin Sci (Lond); 2021 Apr; 135(7):847-864. PubMed ID: 33755094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression.
    Kronschnabl P; Grünweller A; Hartmann RK; Aigner A; Weirauch U
    Int J Oncol; 2020 Feb; 56(2):448-459. PubMed ID: 31894300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
    Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma.
    Zhou Q; Tian W; Jiang Z; Huang T; Ge C; Liu T; Zhao F; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
    Cancer Res; 2021 Mar; 81(5):1361-1374. PubMed ID: 33361392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway.
    Yang Q; Xie B; Tang H; Meng W; Jia C; Zhang X; Zhang Y; Zhang J; Li H; Fu B
    J Exp Clin Cancer Res; 2019 Jun; 38(1):263. PubMed ID: 31208444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
    Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
    DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
    Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
    Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma.
    Zhu WP; Liu ZY; Zhao YM; He XG; Pan Q; Zhang N; Zhou JM; Wang LR; Wang M; Zhan DH; Ma DN; Wang L
    Cell Death Dis; 2018 Jan; 9(2):69. PubMed ID: 29358721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
    Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
    Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCA3 contributes to the malignant progression of hepatocellular carcinoma through AKT activation and NF-κB translocation.
    Ma D; Li M; Su J; Zhang S
    Exp Cell Res; 2018 Jan; 362(1):142-151. PubMed ID: 29133128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
    Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
    Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-κB-dependent expression of interleukin-8.
    Lee EK; Kim DG; Kim JS; Yoon Y
    Cancer Res; 2011 Nov; 71(21):6827-35. PubMed ID: 21917729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
    Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
    Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.